Invega Sustenna Injection 75 mg contains Paliperidone Palmitate, a long-acting atypical antipsychotic designed for the management of schizophrenia and schizoaffective disorders in adults. Paliperidone, the active metabolite of risperidone, works by modulating dopamine and serotonin receptors in the brain, helping restore chemical balance and improve thought processes, mood, and behavior in patients with psychotic disorders.

This long-acting injectable formulation is designed for monthly administration, ensuring sustained therapeutic levels of the medication without the need for daily oral dosing. Invega Sustenna provides consistent symptom control, reduces the risk of relapse, and improves adherence in patients who may have difficulty maintaining regular oral medication schedules. The prefilled syringe allows precise dosing and convenient administration under medical supervision.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Invega Sustenna Injection 75 mg is indicated for:

• Treatment and maintenance therapy of schizophrenia in adults

• Management of schizoaffective disorder, as part of a comprehensive treatment plan

• Prevention of relapse in patients stabilized on paliperidone or risperidone

This formulation is particularly beneficial for patients who struggle with medication adherence or require long-term antipsychotic therapy for symptom stabilization.

Dosage and Administration

• The recommended starting dose is 150 mg on Day 1, followed by 100 mg on Day 8, both administered via intramuscular (IM) injection in the deltoid muscle

• Subsequent maintenance doses are 75 mg once monthly, administered in either the deltoid or gluteal muscle

• Dose adjustments may be required based on individual patient response, tolerability, and clinical judgment

• The injection should be administered by a healthcare professional familiar with the proper intramuscular injection technique

Patients should be monitored for efficacy, adverse reactions, and any potential extrapyramidal symptoms during therapy.

Precautions and Warnings

• Use cautiously in patients with a history of cardiovascular disorders, including QT prolongation, arrhythmias, or heart disease

• Monitor for signs of neuroleptic malignant syndrome, tardive dyskinesia, or orthostatic hypotension

• Elderly patients with dementia-related psychosis have an increased risk of mortality; Invega Sustenna is not approved for this population

• Avoid abrupt discontinuation to reduce the risk of relapse or symptom exacerbation

• Monitor metabolic parameters, including weight, blood glucose, and lipid levels, as atypical antipsychotics may cause metabolic changes

Patients should be counseled to report symptoms such as dizziness, palpitations, muscle stiffness, or unusual movements promptly.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Invega Sustenna Injection 75 mg is generally well tolerated. Common side effects include:

• Injection site reactions, such as pain, redness, or swelling

• Dizziness or sedation

• Weight gain

• Extrapyramidal symptoms, including tremor or rigidity

• Increased prolactin levels, which may lead to breast enlargement or menstrual irregularities

Severe adverse effects, such as neuroleptic malignant syndrome, significant cardiovascular events, or severe allergic reactions, are rare but require immediate medical attention.

Storage

Store below 30°C, protected from light, and do not freeze. Keep the prefilled syringe in the original packaging until use, and out of reach of children.

Invega Sustenna Injection 75 mg/Prefilled Syringe (Paliperidone Palmitate) provides a safe, effective, and convenient long-acting antipsychotic option, supporting symptom control, relapse prevention, and improved treatment adherence in patients with schizophrenia and schizoaffective disorder.